(Q30407946)

English

Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

emerging communicable disease

1 reference

based on heuristic

inferred from title

1

object named as

Thomas R Kreil

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Hartmut J Ehrlich

10

object named as

Hartmut J Ehrlich

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

11

object named as

P Noel Barrett

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

John K Mc Vey

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Laura Shau-Ping Lei

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Laureano Camacho

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Walter Wodal

5

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Astrid Kerschbaum

6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Edy Segura

7

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Etienne Vandamme

8

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Patrick Gavit

9

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Donald A Baker

12

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

publication date

7 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

803-809

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Passive immunity in prevention and treatment of infectious diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Antibody-based therapies for emerging infectious diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Hark back: passive immunotherapy for influenza and other serious infections.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Passive Immunization Against Poliomyelitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

West Nile virus neutralization by US plasma-derived immunoglobulin products

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Influenza pathogenesis: lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Inactivation and removal of influenza A virus H1N1 during the manufacture of plasma derivatives.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

H5N1 influenza virus and the safety of plasma products.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Response to a monovalent 2009 influenza A (H1N1) vaccine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Significant neutralizing activity of human immunoglobulin preparations against pandemic 2009 H1N1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Fatalities associated with the 2009 H1N1 influenza A virus in New York city

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03347.X

21 January 2018

Identifiers

10.1111/J.1537-2995.2011.03347.X

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30407946&oldid=1549716724"